ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "osteoporosis"

  • Abstract Number: 1029 • ACR Convergence 2024

    An Analysis of Osteoporosis Screening in Males vs. Females Across Lehigh Valley Health Network

    Benjamin Wolff1, Ryan Bigelsen2, Kathryn Zaffiri2, Susan Kim3 and Philip Dunn4, 1Lehigh Valley Health Network, Macungie, PA, 2Lehigh Valley Health Network, Allentown, PA, 3Lehigh Valley Hospital Network, Allentown, PA, 4Lehigh Valley Health Network, Emmaus, PA

    Background/Purpose: Osteoporosis is a widely recognized disease of the bone where bone mineral density is decreased leading to increased risk for fracture. Bone mineral density…
  • Abstract Number: 2118 • ACR Convergence 2024

    Cytotoxic T Lymphocyte Antigen-4 Improves Osteoporosis in Patient with Rheumatoid Arthritis

    Yen-An Chang1 and Ming‑Han Chen2, 1Division of Allergy, Immunology, Rheumatology/Department of Medicint/Taipei Veterans General Hospital, Taipei City, Taiwan (Republic of China), 2Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan

    Background/Purpose: Rheumatoid arthritis (RA) is recognized as a risk factor for osteoporosis.  Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) acts as an inhibitory regulator post-T cell activation,…
  • Abstract Number: 2140 • ACR Convergence 2024

    Frailty Is Associated with Lower Bone Mineral Density in US Veterans with Rheumatoid Arthritis

    Katherine Wysham1, Hannah Brubeck2, Kylie Riggles3, Riley Bass4, Elizabeth Wahl2, Radhika Narla5, Namrata Singh6, ariela orkaby7, Joshua Baker8, Patricia Katz9, Dolores Shoback10 and Jose Garcia11, 1VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 2VA Puget Sound Health Care System, Seattle, WA, 3VA Puget Sound Health Care System, Bellevue, WA, 4VA Puget Sound Health Care System, Seattle, 5VA Puget Sound Healthcare System, Seattle, WA, Seattle, WA, 6University of Washington, Bellevue, WA, 7New England VA Geriatric Research Education and Clinical Center/Boston VA/Division of Aging, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 8Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, 9University of California, San Francisco, San Francisco, CA, 10San Francisco VA/University of California, San Francisco, San Francisco, CA, 11VA Puget Sound Health Care System/University of Washington, Seattle, WA

    Background/Purpose: Frailty represents a state of increased vulnerability to poor outcomes after physiologic stressors, and occurs at higher rates and younger ages in RA. Frailty…
  • Abstract Number: 1033 • ACR Convergence 2024

    Osteoporosis and Cardiovascular Disease: Mortality Trends Among Adults in the United States from 1999 to 2020

    Muhammad Naveed1, Farman Ali2, Ahila Ali1, Bazil Azeem3, Faizan Ahmed4, Rabia Iqbal1, Muhammad Omer Rehan1, Nouman Shafique5, Syed Ishaq6, Aman Ullah7 and Sherif Eltawansy8, 1Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan, 2Corewell Health, Dearborn Hospital, Dearborn, MI, Dearborn, MI, 3Shaheed Mohtarma Benazir Bhutto Medical College Liyari, Karachi, Pakistan, 4Ameer-ud-Din Medical College, Lahore, Pakistan, 5AdventHealth Orlando, Orlando, FL, 6Sinai Hospital of Baltimore, Baltimore, MD, 7SSM Health St Louis University Hospital, St. Louis, MO, 8Jersey Shore University Medical Centre, Neptune, NJ

    Background/Purpose: Osteoporosis and cardiovascular disease (CVD) represent significant public health concerns. This study investigates the trends and demographic disparities in mortality due to osteoporosis and…
  • Abstract Number: 2120 • ACR Convergence 2024

    EvaluationofBone Mineral Densityand Trabecular Bone Score in JuvenileSystemicLupusErythematosusPatientsUsing Dual-Energy X-rayAbsorptiometry

    BEATRIZ ROSA1, Melissa Fraga1, Erica Barbosa1, Jade Dib Fernandez2, Marcelo Pinheiro3 and Maria Teresa Terreri4, 1Universidade Federal de São Paulo, São Paulo, SP, Brazil, 2UNIFESP-EPM, São Paulo, SP, Brazil, 3UNIFESP/ EPM, São Paulo, SP, Brazil, 4UNIFESP, São Paulo, SP, Brazil

    Background/Purpose: Juvenile Systemic Lupus Erythematosus (jSLE) is a multisystem inflammatory disease associated with bone mass loss. This loss can be evaluated by using the bone…
  • Abstract Number: 2141 • ACR Convergence 2024

    Glucocorticoid Therapy-Associated Bone Fractures Are Associated with Osteoporosis Underscreening in Patients with Rheumatoid Arthritis

    Marlene Marte Furment1 and Andras Perl2, 1SUNY Upstate Medical University, Syracuse, NY, 2SUNY, Syracuse, NY

    Background/Purpose: The majority of bone loss happens within 6 months of glucocorticoid treatment. Per the 2022 American College of Rheumatology (ACR) Glucocorticoid-Induced Osteoporosis Guidelines it…
  • Abstract Number: 1055 • ACR Convergence 2024

    Impact of Provider Billing vs. Pharmacy Dispensation for Romosozumab Treatment Discontinuation Among U.S. Postmenopausal Women with Osteoporosis

    Ye Liu1, Jingyi Zhang1, Tarun Arora2, Bisakha Sen1, Kenneth Saag3 and Jeffrey Curtis3, 1University of Alabama at Birmingham, Birmingham, AL, 2FASTER, Birmingham, AL, 3The University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Medicare Part B drug expenditures have increased due to the rising use of expensive specialty drugs like provider-administered biologics. These medications can also be…
  • Abstract Number: 2122 • ACR Convergence 2024

    Rheum for Improvement: Screening and Treatment of Glucocorticoid Induced Osteoporosis

    Jaspreet Bahia1, Christian Steppe2, Hannah Brubeck3, Radhika Narla2, George Mount4, Elizabeth Wahl5 and Katherine Wysham6, 1University of Washington, SEATTLE, WA, 2VA Puget Sound Healthcare System, Seattle, WA, Seattle, WA, 3VA Puget Sound Health Care System, Seattle, WA, 4Madigan Army Medical Center, Lakewood, WA, 5VA Puget Sound Healthcare System, Seattle, WA, 6VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA

    Background/Purpose: Glucocorticoid induced osteoporosis (GIOP) accelerates bone loss and increases fracture risk. We evaluated GIOP screening and prescribing patterns in our Veterans Affairs (VA)-based academic…
  • Abstract Number: 2142 • ACR Convergence 2024

    Comparison of Bone Mineral Density at the Distal Radius, Hip, and Lumbar Spine in Female Patients Undergoing Surgery for Proximal Femur or Distal Radius Fractures: Implications for Osteoporosis Diagnosis

    KEN NAKASEKO, Department of Orthopaedic Surgery and Rheumatology, Kuwana City Medical Center, Kuwana Mie, Japan

    Background/Purpose: Osteoporosis is often diagnosed based on bone mineral density (BMD) measurements at the hip or lumbar spine. However, our previous study reported that 38%…
  • Abstract Number: 1061 • ACR Convergence 2024

    Utilization of Electronic Health Record System to Improve Glucocorticoid Induced Osteoporosis Screening and Treatment

    Anupama Shahane1, Marissa Blum2, Andrew Kanoff3, Kristel Frey4, Sean Looby5 and Nora Sandorfi1, 1University of Pennsylvania, Philadelphia, PA, 2Temple University Health System, Philadelphia PA, Philadelphia, 3University of Pennsylvania, Philadelphia, PA, Philadelphia, PA, 4University of Pennsylvania, Philadelphia PA, Philadelphia, PA, 5University of Pennsylvania, Philadelphia PA, Philadelphia

    Background/Purpose: Osteoporosis is the most common bone disease leading to fragility fractures associated with significant morbidity and increased mortality (1). Glucocorticoids (GC) are widely used…
  • Abstract Number: 2123 • ACR Convergence 2024

    Epidemiology of Bone Health and Fracture in Gout Patients

    Emily Holladay1, Alexis Woods2, Lissa Padnick-Silver3, Fenglong xie4, Jingyi Zhang5, Angelo Gaffo5, Jeffrey Curtis6 and Brian LaMoreaux2, 1University of Alabama at Birmingham, Edmond, OK, 2Amgen, Thousand Oaks, CA, 3Amgen, Thousand Oaks, 4University of Alabama at Birmingham; Illumination Health, Birmingham, AL, 5University of Alabama at Birmingham, Birmingham, AL, 6FASTER Medicine, Hoover, AL

    Background/Purpose: Gout is an erosive arthropathy, and gout patients have been shown to have a higher occurrence of osteoporosis and fracture. This study evaluated bone…
  • Abstract Number: 2143 • ACR Convergence 2024

    Analysis of Effectiveness and Safety of Romosozumab in Patients with Very High Risk of Fracture in a Spanish Population

    Marina soledad Moreno Garcia1, Roxana González Mazario2, yedra uson Rodriguez3, Erardo meriño Ibarra4, Emilio Giner5, Juan Carlos Cobeta García6, Marilia Arce Benavente7, maria Dolores Fábregas canales8, Julia Ullier Bellmunt3, Giuliano Boselli3, pilar martinez Valles7, Jorge Juan Fragío Gil9, carlos Vazquez Galeano7 and Ana Turrion Nieves10, 1hospital Miguel Servet . Zaragoza, Zaragoza, Aragon, Spain, 2Hospital General de Valencia, Valencia, Comunidad Valenciana, Spain, 3hospital miguel servet, zaragoza, Aragon, Spain, 4Hospital San Jorge Huesca, zaragoza, 5Hospital Royo Villanova, Teruel, Spain, 6Hospital Ernest Lluch, zaragoza, 7hospital miguel servet, Zaragoza, 8Hospital de Barbastro, Huesca, Spain, 9Hospital General Universitario, Valencia, Comunidad Valenciana, Spain, 10Rheumatology Department, Hospital Universitario Virgen de la Vega, Salamanca, Spain

    Background/Purpose: Excluding clinical trials, there is limited evidence on the effect of 12 months of romosozumab treatment on increasing bone mineral density (BMD) in real-world…
  • Abstract Number: 1620 • ACR Convergence 2023

    Cardiovascular Risk and Fracture Risk Among Women Initiating Treatment with Romosozumab or Denosumab

    Ye Liu1, Tarun Arora2, S. Bobo Tanner3 and Jeffrey Curtis1, 1University of Alabama at Birmingham, Birmingham, AL, 2Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, 3Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Romosozumab (romo) and denosumab (dmab) are recommended for postmenopausal women with osteoporosis (OP) at high risk of fracture. The U.S. prescribing information includes a…
  • Abstract Number: 2009 • ACR Convergence 2023

    Screening and Treatment of Low Bone Mineral Density in Allogeneic Hematopoietic Cell Transplant Patients

    Perry Fuchs, Christina Ferraro, Chao Zhang, Chad Deal, Betty Hamilton and Sarah Keller, Cleveland Clinic Foundation, Cleveland, OH

    Background/Purpose: Bone mineral density (BMD) loss and fracture are important causes of increased morbidity following allogeneic hematopoietic stem cell transplant (allo-HCT).Recent societal recommendations support screeningDual…
  • Abstract Number: 2530 • ACR Convergence 2023

    Risk Evaluation of Osteoporotic Fractures Following Lung Transplantation (LT): A Retrospective Cohort Study Conducted at an International Transplant Center

    Sarah Keller1, Adil Vural2, Jennifer Varley2, Komal Mushtaq2, Walaa Abu Alya3, Neel Tapryal2, Hassan Shaheen3, Marie Budev2, Abby Abelson2 and Chad Deal1, 1Cleveland Clinic Foundation, Cleveland, OH, 2Cleveland Clinic, Cleveland, OH, 3Cleveland Clinic Fairview Hospital, Cleveland, OH

    Background/Purpose: Osteoporotic fractures are a well-known complication in LT recipients, significantly impacting their quality of life. Specific risk factors for these fractures in LT recipients…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology